Zenas BioPharma, Inc. (NASDAQ: ZBIO) is a Healthcare company (Biotechnology) with a market capitalization of $1.9B. The Maz Rating grades it against the other companies in its sector.
Zenas BioPharma, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $27.72, Zenas BioPharma, Inc. trades at 172.2x sales and 8.7x book value. Over the last twelve months it generated about $11M of revenue and a net loss of $676M. It runs a gross margin of -656.6%, an operating margin of -4785.5% and a net margin of -4925.5%. It shows return on equity of -208.9%, return on invested capital of -86.0% and a free cash flow yield of -12.8%. On the balance sheet: a debt-to-equity ratio of 1.42 and a current ratio of 9.42. Over the past 52 weeks the share price ranged from $13.50 to $44.60, with a beta of -1.02.
Zenas BioPharma, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 4 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Zenas BioPharma, Inc. (ZBIO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 16.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 34.7% / 30% · Interest income / Revenue 58.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 16.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 31.4% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 58.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 16.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 31.4% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 58.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 44.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 91.3% / 33.33% · Receivables / Avg Assets (4Q) 0.08% / 33.33% · Interest income / Revenue 58.0% / 5% | Fail |
| FTSE | Debt / Total Assets 44.3% / 33.33% · (Cash+ST Inv) / Total Assets 86.7% / 33.33% · (Cash+Recv) / Total Assets 86.7% / 33.33% · Interest income / Revenue 58.0% / 5% | Fail |
No. As of September 2026, Zenas BioPharma, Inc. (ZBIO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Zenas BioPharma, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 58.0% of each dividend: Zenas BioPharma, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.